Sphere Fluidics, a leading provider of innovative droplet-based microfluidics solutions for functional profiling of single cells at scale, today announced a significant expansion of its global commercial presence. The Company has established a new direct sales and support channel for customers in North America and made several commercial leadership changes globally. These milestones reflect the ongoing strategic focus on operational scale-up to address demand for the Company's Cyto-Mine ® platform and provide local specialized support.
As North America Commercial Director, Dr. Erroll Rueckert has joined to lead a new and rapidly expanding sales team for the American market. Central to this role is building a new direct sales channel in this key region, streamlining customer access to its portfolio of products, including the recently announced Cyto-Mine Chroma platform1.
Erroll has strong commercial and technical expertise in single cell analysis, spatial biology, and genomics. Prior to Sphere, Erroll held roles of increasing responsibility at NanoString and Lightcast Discovery. Dr.
Graeme Daniels, VP of Commercial (EMEA), oversees the Company's commercial team in EMEA, which is continuing to significantly expand in response to a growing European customer base. An important part of the expansion will be to pivot from distributed to direct sales in Germany, France, Benelux, and Nordic countries. Graeme brings extensive commercial leadership experience honed at companies provid.